Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in Relapsed or Metastatic Triple Receptor Negative Breast Cancer
NCT03692689Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sct200 in triple-negative breast cancer (TNBC), sponsored by Sinocelltech Group Limited. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
sct200
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03692689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692689.